

Adrenal Hormone Report; saliva



Order: Sample Report HOR02

Client #: 38596

Regenerus Laboratories Ltd Aero 14, Redhill Aerodome, Kings Mill

Ln

Redhill Surrey, RH1 5YP

United Kingdom

Sample Report HOR02 **Age:** 62 **DOB:** 07/08/1957

Sex: Male

Body Mass Index (BMI): 27.6


Sample Collection Date/Time
Date Collected 07/10/2019

AM3007/10/2019 05:30Noon07/10/2019 13:45Evening07/10/2019 18:00Night07/10/2019 22:30

 Date Received
 07/16/2019

 Date Reported
 07/19/2019

Analyte	Result	Unit	L	WRI	H Optimal Range	Reference Interval
Cortisol AM30	4.9	nmol/L	+		14.0 – 25.0	7.0 – 30.0
Cortisol Noon	5.4	nmol/L		\rightarrow	5.0 – 10.0	2.1 – 14.0
Cortisol Evening	2.0	nmol/L		\rightarrow	2.0-5.0	1.5 – 8.0
Cortisol Night	1.5	nmol/L		\rightarrow	1.0 – 4.0	0.33-7.0
DHEA*	199	pg/mL		\rightarrow		137 – 336



Hormone Comments:

The diurnal cortisol pattern is consistent with established (Phase 3)HPA axis (adrenal gland) dysfunction.

Notes

RI= Reference Interval, L (blue) = Low (below RI), WRI (green) = Within RI (optimal), WRI (yellow) = Within RI (not optimal), H (red) = High (above RI) The current samples are routinely held three weeks from receipt for additional testing.

*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Methodology: Enzyme Immunoassay





Order: Sample Report HOR02

Client #: 38596

Regenerus Laboratories Ltd Aero 14, Redhill Aerodome, Kings Mill

Ln

Redhill Surrey, RH1 5YP

United Kingdom

Sample Report HOR02 Age: 62 DOB: 07/08/1957

Sex: Male

Body Mass Index (BMI): 27.6

Sample Collection Date/Time
Date Collected 07/10/2019

AM3007/10/2019 05:30Noon07/10/2019 13:45Evening07/10/2019 18:00Night07/10/2019 22:30

 Date Received
 07/16/2019

 Date Reported
 07/19/2019

Analyte	Result	Unit	L	WRI	Н	Reference Interval	Supplementation Range**
Estradiol (E2)	1.8	pg/mL		\rightarrow		< 2.5	
Progesterone (Pg)	45	pg/mL				< 94	500 – 3000
Pg/E2 Ratio	25.0		1			200-300	
Testosterone	62	pg/mL		\rightarrow		30-143	110 – 500
DHEA*	199	pg/mL		\rightarrow		137 – 336	



Hormone Comments:

- The low Pg/E2 ratio is consistent with progesterone insufficiency (estrogen dominance), which may increase the risk of prostate gland enlargement and cancer. Supplementation with topical progesterone to correct this relative deficiency is a consideration.
- Testosterone level may be adequate depending upon clinical presentation.

Notes:

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI) The current samples are routinely held three weeks from receipt for additional testing.

The Pg/E2 ratio is an optimal range established based on clinical observation. Progesterone supplementation is generally required to achieve this level in men and postmenopausal women.

*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

**If supplementation is reported then the supplementation ranges will be graphed. The supplementation ranges depicted are for informational purposes only and were derived from a cohort of adult men and women utilizing physiologic transdermal bioidentical hormone therapy.

Methodology: Enzyme Immunoassay